November 17, 2005 |
British drug maker AstraZeneca didn't deceive consumers about the benefits of its Nexium heartburn medication, a federal judge ruled as she threw out a class-action lawsuit against the company. U.S. District Judge Sue Robinson in Wilmington, Del., granted AstraZeneca's motion to dismiss the case after finding that statements made in advertising were consistent with the label approved by the Food & Drug Administration.
July 12, 2005 |
AstraZeneca will pay as much as $340 million to Avanir Pharmaceuticals to develop experimental heart-disease treatments. The companies will work to develop medicines from so-called reverse cholesterol transport enhancing compounds, which may allow the body to reverse damage to blood vessels, AstraZeneca said. AstraZeneca will pay $10 million now with as much as $330 million linked to the experimental drugs meeting development goals, the companies said.
June 7, 2005 |
AstraZeneca's Crestor cholesterol drug may have triggered a temporary weakening in a 67-year-old woman's heart, Mayo Clinic doctors said in a letter published in the Annals of Internal Medicine. Kidney and muscle complications from Crestor may have caused the woman's heart to pump about a fifth as much blood as normal on each beat, James Ireland, a Mayo Clinic doctor, said in Rochester. He was one of four authors of the letter, published under the heading "Clinical Observation."
March 12, 2005 |
AstraZeneca has received its second warning in four months from the U.S. Food and Drug Administration over what the agency says are misleading claims in its ads for cholesterol-lowering medicine Crestor, the company said in New York. The latest letter said claims that Crestor lowers cholesterol better than Pfizer Inc.'s Lipitor were misleading because it cherry picked results from a study comparing the two medicines.
March 4, 2005 |
Pharmaceutical giant AstraZeneca told an FDA committee this week that the failure of its last-chance cancer drug, Iressa, to significantly improve survival rates in a clinical trial was a surprise and that a review was underway to determine why the product didn't do better. Iressa won Food and Drug Administration approval in 2003 for advanced lung cancer patients who had exhausted standard therapy after studies showed that it shrank tumors in some terminally ill patients.
December 23, 2004 |
The Food and Drug Administration is seeking to block an ad touting the safety of the cholesterol drug Crestor, calling the claims misleading. The agency asked the drug maker, AstraZeneca, to "immediately cease the dissemination" of the ad. AstraZeneca spokeswoman Emily Denney said that the ad ran for only a short time and that the FDA had been advised that it was no longer being used.